Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Change in Accured Expenses: 2022-2025

Historic Change in Accured Expenses for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $4.9 million.

  • Stoke Therapeutics' Change in Accured Expenses rose 751.67% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 6169.17%. This contributed to the annual value of $3.1 million for FY2024, which is 196.26% up from last year.
  • As of Q3 2025, Stoke Therapeutics' Change in Accured Expenses stood at $4.9 million, which was up 76.53% from $2.8 million recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Change in Accured Expenses peaked at $4.9 million during Q3 2025, and registered a low of -$4.4 million during Q2 2023.
  • Over the past 3 years, Stoke Therapeutics' median Change in Accured Expenses value was $2.0 million (recorded in 2023), while the average stood at $1.1 million.
  • In the last 5 years, Stoke Therapeutics' Change in Accured Expenses crashed by 677.39% in 2023 and then skyrocketed by 751.67% in 2025.
  • Quarterly analysis of 4 years shows Stoke Therapeutics' Change in Accured Expenses stood at $199,000 in 2022, then plummeted by 677.39% to -$1.1 million in 2023, then skyrocketed by 289.64% to $2.2 million in 2024, then surged by 751.67% to $4.9 million in 2025.
  • Its Change in Accured Expenses was $4.9 million in Q3 2025, compared to $2.8 million in Q2 2025 and $4.7 million in Q1 2025.